肿瘤标志物在食管鳞状细胞癌中的应用被引量：1

Application of tumor markers in esophageal squamous cell carcinoma

导出

摘要对细胞角蛋白19片断（CYFRA21—1）、鳞状细胞癌抗原（SCC）等常规食管鳞状细胞癌（简称鳞癌）肿瘤标志物应用状况，肿瘤标志物在食管鳞癌早期诊断、预测化放疗敏感性、监测术后复发和转移、判断预后方面的研究进展作一介绍。虽然食管鳞癌肿瘤标志物的研究和报道较多，但是尚无令人满意的肿瘤标志物。蛋白质组学技术已开始用于食管鳞癌肿瘤标志物的寻找，随着分子生物学技术的进步，有望寻找到理想的肿瘤标志物，为食管鳞癌的诊断治疗提供便捷途径。 The determination of tumor markers is of great value for esophageal squamous cell carcinoma. This article reviews the application status of routine tumor markers and the progression on the role of tumor markers in early diagnosis, predicting chemotherapy or radiotherapy response, monitoring disease recurrence and evaluation of prognosis in esophageal squamous cell carcinoma.

作者龚磊张晓东

机构地区北京大学临床肿瘤学院北京肿瘤医院北京市肿瘤防治研究所消化道肿瘤内科

出处《肿瘤研究与临床》 CAS 2009年第8期433-435,共3页 Cancer Research and Clinic

关键词食管肿瘤肿瘤鳞状细胞肿瘤标记生物学 Esophageal neoplasms Neoplasms, squamous cell Tumor markers, biological

分类号 R735.1 [医药卫生—肿瘤] R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献27

1王伟,张飞雄,李兆申.胰腺肿瘤标志物的研究进展[J].世界华人消化杂志,2007,15(34):3604-3610. 被引量：17
2Munck-Wikland E, Kuylenstiema R, Lindholm J, et al. Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus. Anticancer Res, 1990, 10: 703-708.
3McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker ofoesophageal cancer. Br J Cancer, 1959, 60:249-251.
4Kosugi S, Nishimaki T, Kanda T, et al. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg, 2004, 28: 680-685.
5Ychou M, Khemissa-Akouz F, Kramar A, et al. A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma. Bull Cancer, 2001, 88: 1023-1027.
6Yamamoto K, Oka M, Hayashi H, et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer, 1997, 79: 1647-1655.
7Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer, 2000, 89: 1413-1417.
8Takahashi K, Miyashita M, Nomura T, et al. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus, 2007, 20:117-122.
9Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res, 2000,6:4249-52.
10Sobti RC, Parashar K. A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat Res, 1998, 422: 271-277.

二级参考文献69

1Fleisher M, A.M. D, Sturgeon CM, Lamerz R, Witliff JL. Tumor markers: Physiology, Pathobiology, Technology and Clinical Applications. Chicago: AACC press, 2002.32.
2Hyoty M, Hyoty H, Aaran RK, Airo I, Nordback I. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992,158:173-179.
3Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001, 121:640-645.
4Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994, 120:494-497.
5Shahangian S, Fritsche HA Jr, Hughes JI, Gelder FB. Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas. Clin Chem 1989,35:405-408.
6Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 2005, 18: 779-787.
7Schneider J, Schulze G. Comparison of tumor M2- pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003, 23:5089-5093.
8Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M. Identification of hepatocarcinoma- intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002,62:1868-1875.
9Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003,138: 951-955. discussion 955-956.
10Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002, 22:2311-2316.